scholarly journals Effective Mobilization of Very Small Embryonic-Like Stem Cells and Hematopoietic Stem/Progenitor Cells but Not Endothelial Progenitor Cells by Follicle-Stimulating Hormone Therapy

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Monika Zbucka-Kretowska ◽  
Andrzej Eljaszewicz ◽  
Danuta Lipinska ◽  
Kamil Grubczak ◽  
Malgorzata Rusak ◽  
...  
Keyword(s):  
Stem Cells ◽  
Hormone Therapy ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Peripheral Blood ◽  
Follicle Stimulating Hormone ◽  
Endothelial Progenitor ◽  
Hematopoietic Stem ◽  
Cell Phenotypes ◽  
Stimulating Hormone

Recently, murine hematopoietic progenitor stem cells (HSCs) and very small embryonic-like stem cells (VSELs) were demonstrated to express receptors for sex hormones including follicle-stimulating hormone (FSH). This raised the question of whether FSH therapy at clinically applied doses can mobilize stem/progenitor cells in humans. Here we assessed frequencies of VSELs (referred to as Lin−CD235a−CD45−CD133+cells), HSPCs (referred to as Lin−CD235a−CD45+CD133+cells), and endothelial progenitor cells (EPCs, identified as CD34+CD144+, CD34+CD133+, and CD34+CD309+CD133+cells) in fifteen female patients subjected to the FSH therapy. We demonstrated that FSH therapy resulted in statistically significant enhancement in peripheral blood (PB) number of both VSELs and HSPCs. In contrast, the pattern of responses of EPCs delineated by different cell phenotypes was not uniform and we did not observe any significant changes in EPC numbers following hormone therapy. Our data indicate that FSH therapy mobilizes VSELs and HSPCs into peripheral blood that on one hand supports their developmental origin from germ lineage, and on the other hand FSH can become a promising candidate tool for mobilizing HSCs and stem cells with VSEL phenotype in clinical settings.

scholarly journals Very Small Embryonic-Like Stem Cells, Endothelial Progenitor Cells, and Different Monocyte Subsets Are Effectively Mobilized in Acute Lymphoblastic Leukemia Patients after G-CSF Treatment

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Andrzej Eljaszewicz ◽  
Lukasz Bolkun ◽  
Kamil Grubczak ◽  
Malgorzata Rusak ◽  
Tomasz Wasiluk ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Lymphoblastic Leukemia ◽  
Monocyte Subsets ◽  
Endothelial Progenitor ◽  
Hematopoietic Stem ◽  
Cd34 Cells

Background. Acute lymphoblastic leukemia (ALL) is a malignant disease of lymphoid progenitor cells. ALL chemotherapy is associated with numerous side effects including neutropenia that is routinely prevented by the administration of growth factors such as granulocyte colony-stimulating factor (G-CSF). To date, the effects of G-CSF treatment on the level of mobilization of different stem and progenitor cells in ALL patients subjected to clinically effective chemotherapy have not been fully elucidated. Therefore, in this study we aimed to assess the effect of administration of G-CSF to ALL patients on mobilization of other than hematopoietic stem cell (HSCs) subsets, namely, very small embryonic-like stem cells (VSELs), endothelial progenitor cells (EPCs), and different monocyte subsets. Methods. We used multicolor flow cytometry to quantitate numbers of CD34+ cells, hematopoietic stem cells (HSCs), VSELs, EPCs, and different monocyte subsets in the peripheral blood of ALL patients and normal age-matched blood donors. Results. We showed that ALL patients following chemotherapy, when compared to healthy donors, presented with significantly lower numbers of CD34+ cells, HSCs, VSELs, and CD14+ monocytes, but not EPCs. Moreover, we found that G-CSF administration induced effective mobilization of all the abovementioned progenitor and stem cell subsets with high regenerative and proangiogenic potential. Conclusion. These findings contribute to better understanding the beneficial clinical effect of G-CSF administration in ALL patients following successful chemotherapy.

Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood

Blood ◽  
2007 ◽  
Vol 110 (1) ◽  
pp. 151-160 ◽  
Author(s):  
Masumi Nagano ◽  
Toshiharu Yamashita ◽  
Hiromi Hamada ◽  
Kinuko Ohneda ◽  
Ken-ichi Kimura ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Aldh Activity ◽  
Endothelial Progenitor ◽  
Hematopoietic Stem

Umbilical cord blood (UCB) has been used as a potential source of various kinds of stem cells, including hematopoietic stem cells, mesenchymal stem cells, and endothelial progenitor cells (EPCs), for a variety of cell therapies. Recently, EPCs were introduced for restoring vascularization in ischemic tissues. An appropriate procedure for isolating EPCs from UCB is a key issue for improving therapeutic efficacy and eliminating the unexpected expansion of nonessential cells. Here we report a novel method for isolating EPCs from UCB by a combination of negative immunoselection and cell culture techniques. In addition, we divided EPCs into 2 subpopulations according to the aldehyde dehydrogenase (ALDH) activity. We found that EPCs with low ALDH activity (Alde-Low) possess a greater ability to proliferate and migrate compared to those with high ALDH activity (Alde-High). Moreover, hypoxia-inducible factor proteins are up-regulated and VEGF, CXCR4, and GLUT-1 mRNAs are increased in Alde-Low EPCs under hypoxic conditions, while the response was not significant in Alde-High EPCs. In fact, the introduction of Alde-Low EPCs significantly reduced tissue damage in ischemia in a mouse flap model. Thus, the introduction of Alde-Low EPCs may be a potential strategy for inducing rapid neovascularization and subsequent regeneration of ischemic tissues.

The relationship between mesenchymal stem cells, monocyte-macrophages, endothelial progenitor cells, and prognosis of hepatocellular carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14507-e14507
Author(s):  
Kun Yan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Peripheral Blood ◽  
Diagnostic Value ◽  
Endothelial Progenitor ◽  
Blood Samples ◽  
The Relationship

e14507 Background: This experiment is designed to investigate the clinical correlation between mesenchymal stem cells, macrophages, endothelial progenitor cells and hepatocellular carcinoma, furthermore to assess their diagnostic value. Methods: A prospective cohort study was conducted to collect patients who admitted to the Department of General Surgery, Second Affiliated Hospital of Xi'an Jiaotong University. The peripheral blood samples of patients with hepatocellular carcinoma (HCC) who diagnosed by pathology from September 2014 to August 2016 were collected. The mesenchymal stem cells, macrophages and endothelial progenitor cells (EPCs) were analyzed by flow cytometers. Results: There was no correlation between hepatocellular carcinoma and peripheral blood mesenchymal stem cells (p > 0.05), and there was correlation between hepatocellular carcinoma and macrophages and endothelial progenitor cells (p < 0.01). The positive correlated coefficient is 0.938 in macrophages, and the negative correlated coefficient is -0.835 in the endothelial progenitor cells. Conclusions: The differentiated pathways of mesenchymal stem cells in hepatocellular carcinoma play key roles in the progression and prognosis of hepatocellular carcinoma.

Sign in / Sign up

Export Citation Format

Share Document